Cargando…

The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.

The novel fluorinated 2-nitroimidazole SR-4554 is undergoing preclinical development as a magnetic resonance spectroscopy and imaging probe for hypoxic tumour cells. We have used electron energy loss spectroscopic analysis (EELS) to show selective reduction and differential subcellular localisation...

Descripción completa

Detalles Bibliográficos
Autores principales: Aboagye, E. O., Lewis, A. D., Johnson, A., Workman, P., Tracy, M., Huxham, I. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034013/
https://www.ncbi.nlm.nih.gov/pubmed/7640211
_version_ 1782136963610968064
author Aboagye, E. O.
Lewis, A. D.
Johnson, A.
Workman, P.
Tracy, M.
Huxham, I. M.
author_facet Aboagye, E. O.
Lewis, A. D.
Johnson, A.
Workman, P.
Tracy, M.
Huxham, I. M.
author_sort Aboagye, E. O.
collection PubMed
description The novel fluorinated 2-nitroimidazole SR-4554 is undergoing preclinical development as a magnetic resonance spectroscopy and imaging probe for hypoxic tumour cells. We have used electron energy loss spectroscopic analysis (EELS) to show selective reduction and differential subcellular localisation of SR-4554 in human ovarian multicellular spheroids. SR-4554 was demonstrated to be metabolised by these A2780 cells under hypoxic but not under normal aerobic cell culture conditions. The EELS technique illustrated that the relative amount of drug within the cytoplasm of cells from both the inner region (150-160 microns from edge) and outer edge of the spheroid did not differ significantly after an initial 3 h incubation with drug. In contrast, an 8-fold differential between the amount of drug retained in the cytoplasm (primarily ribosomes and endoplasmic reticulum) of cells from the inner vs outer regions of the spheroids was observed following a subsequent 2 h 'chase' culture in drug-free medium. Within cells from the hypoxic region of the spheroid, SR-4554 was mainly associated with the endoplasmic reticulum, nucleus and the cytoplasmic side of intracellular vesicles and also to a lesser extent with the nuclear periphery. Interestingly, the drug was only weakly associated with the mitochondria and plasma membrane of the cells. The characteristics of cellular and subcellular distribution of SR-4554 are consistent with the hypothesis that 2-nitroimidazole compounds undergo hypoxia-mediated enzymatic reduction to reactive species. These reactive species are selectively retained in the cells in which they are metabolised through covalent association with subcellular components. These findings provide additional support for the clinical development of the drug as a non-invasive probe for tumour hypoxia and at the same time illustrate the utility of the EELS technique for examining the heterogeneity of drug distribution both between and within cells. IMAGES:
format Text
id pubmed-2034013
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20340132009-09-10 The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. Aboagye, E. O. Lewis, A. D. Johnson, A. Workman, P. Tracy, M. Huxham, I. M. Br J Cancer Research Article The novel fluorinated 2-nitroimidazole SR-4554 is undergoing preclinical development as a magnetic resonance spectroscopy and imaging probe for hypoxic tumour cells. We have used electron energy loss spectroscopic analysis (EELS) to show selective reduction and differential subcellular localisation of SR-4554 in human ovarian multicellular spheroids. SR-4554 was demonstrated to be metabolised by these A2780 cells under hypoxic but not under normal aerobic cell culture conditions. The EELS technique illustrated that the relative amount of drug within the cytoplasm of cells from both the inner region (150-160 microns from edge) and outer edge of the spheroid did not differ significantly after an initial 3 h incubation with drug. In contrast, an 8-fold differential between the amount of drug retained in the cytoplasm (primarily ribosomes and endoplasmic reticulum) of cells from the inner vs outer regions of the spheroids was observed following a subsequent 2 h 'chase' culture in drug-free medium. Within cells from the hypoxic region of the spheroid, SR-4554 was mainly associated with the endoplasmic reticulum, nucleus and the cytoplasmic side of intracellular vesicles and also to a lesser extent with the nuclear periphery. Interestingly, the drug was only weakly associated with the mitochondria and plasma membrane of the cells. The characteristics of cellular and subcellular distribution of SR-4554 are consistent with the hypothesis that 2-nitroimidazole compounds undergo hypoxia-mediated enzymatic reduction to reactive species. These reactive species are selectively retained in the cells in which they are metabolised through covalent association with subcellular components. These findings provide additional support for the clinical development of the drug as a non-invasive probe for tumour hypoxia and at the same time illustrate the utility of the EELS technique for examining the heterogeneity of drug distribution both between and within cells. IMAGES: Nature Publishing Group 1995-08 /pmc/articles/PMC2034013/ /pubmed/7640211 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Aboagye, E. O.
Lewis, A. D.
Johnson, A.
Workman, P.
Tracy, M.
Huxham, I. M.
The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.
title The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.
title_full The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.
title_fullStr The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.
title_full_unstemmed The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.
title_short The novel fluorinated 2-nitroimidazole hypoxia probe SR-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.
title_sort novel fluorinated 2-nitroimidazole hypoxia probe sr-4554: reductive metabolism and semiquantitative localisation in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034013/
https://www.ncbi.nlm.nih.gov/pubmed/7640211
work_keys_str_mv AT aboagyeeo thenovelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT lewisad thenovelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT johnsona thenovelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT workmanp thenovelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT tracym thenovelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT huxhamim thenovelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT aboagyeeo novelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT lewisad novelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT johnsona novelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT workmanp novelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT tracym novelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis
AT huxhamim novelfluorinated2nitroimidazolehypoxiaprobesr4554reductivemetabolismandsemiquantitativelocalisationinhumanovariancancermulticellularspheroidsasmeasuredbyelectronenergylossspectroscopicanalysis